文献速递血栓与止血

天然F8启动子驱动FVIII表达实现血友病A小鼠长期纠正并避免免疫反应

FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
PubMed 文献 · Blood Adv · 2019-01-01

本研究利用天然F8启动子(pF8)驱动基因替代,靶向分泌FVIII的细胞治疗血友病A。在血友病C57/Bl6和129-Bl6小鼠中,LV.pF8.FVIII使FVIII活性最高恢复至25%,持续1年且无抑制剂形成;在已免疫小鼠中可完全逆转抑制剂滴度。Treg缺失后出现抗FVIII抗体,提示Treg参与免疫耐受诱导。

要点

  • LV.pF8.FVIII在血友病小鼠中纠正出血表型,FVIII活性最高恢复至25%,持续1年。
  • 治疗1年无抑制剂形成,且可完全逆转已免疫小鼠的抑制剂滴度并恢复FVIII活性。
  • 去除Treg后出现抗FVIII抗体,提示Treg在免疫耐受诱导中起作用。

核心结论

  • pF8驱动的转基因表达可纠正血友病A小鼠的出血表型,并可能适用于其他需要内皮特异性表达的疾病。

研究设计与样本

  • 研究使用表达绿色荧光蛋白的慢病毒载体(LV.pF8.GFP)在C57Bl/6小鼠中追踪pF8活性,并以LV.pF8.FVIII在血友病C57/Bl6和129-Bl6小鼠中进行基因治疗。
  • 使用密码子优化的FVIII,实验观察期为1年。

主要发现

  • LV.pF8.GFP注射的C57Bl/6小鼠中,绿色荧光蛋白主要表达于肝窦内皮细胞,造血器官中也可检测到少量阳性细胞。
  • LV.pF8.FVIII治疗的血友病C57/Bl6和129-Bl6小鼠出血表型得到纠正,FVIII活性最高恢复至25%,在1年实验期内活性持续且无抑制剂形成。
  • 在FVIII免疫的血友病A小鼠中给予LV.pF8.FVIII,抑制剂滴度完全逆转并恢复治疗性FVIII活性。
  • 在LV治疗的小鼠中去除调节性T细胞(Treg)后,允许抗FVIII抗体形成,表明Treg在免疫耐受诱导中起作用。
  • 所有LV.pF8.FVIII治疗小鼠在注射1年后观察到出血量显著减少,证实长期表型纠正。

关键数值与推荐

  • LV.pF8.FVIII使血友病小鼠FVIII活性最高恢复至25%,持续1年。
  • LV.pF8.FVIII在FVIII免疫的血友病A小鼠中完全逆转抑制剂滴度。
  • 去除Treg后出现抗FVIII抗体形成。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here we describe a successful gene therapy approach for hemophilia A (HA), using the natural F8 promoter (pF8) to direct gene replacement to factor VIII (FVIII)-secreting cells. The promoter sequence and the regulatory elements involved in the modulation of F8 expression are still poorly characterized and biased by the historical assumption that FVIII expression is mainly in hepatocytes. Bioinformatic analyses have highlighted an underestimated complexity in gene expression at this locus, suggesting an activation of pF8 in more cell types than those previously expected. C57Bl/6 mice injected with a lentiviral vector expressing green fluorescent protein (GFP) under the pF8 (lentiviral vector [LV].pF8.GFP) confirm the predominant GFP expression in liver sinusoidal endothelial cells, with a few positive cells detectable also in hematopoietic organs. Therapeutic gene delivery (LV.pF8.FVIII) in hemophilic C57/Bl6 and 129-Bl6 mice successfully corrected the bleeding phenotype, rescuing up to 25% FVIII activity, using a codon-optimized FVIII, with sustained activity for the duration of the experiment (1 year) without inhibitor formation. Of note, LV.pF8.FVIII delivery in FVIII-immunized HA mice resulted in the complete reversion of the inhibitor titer with the recovery of therapeutic FVIII activity. Depletion of regulatory T cells (Tregs) in LV-treated mice allowed the formation of anti-FVIII antibodies, indicating a role for Tregs in immune tolerance induction. The significant blood loss reduction observed in all LV.pF8.FVIII-treated mice 1 year after injection confirmed the achievement of a long-term phenotypic correction. Altogether, our results highlight the potency of pF8-driven transgene expression to correct the bleeding phenotype in HA, as well as potentially in other diseases in which an endothelial-specific expression is required.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Merlin S, Famà R, Borroni E, et al. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice. Blood Adv. 2019. PMID: 30862611. doi:10.1182/bloodadvances.2018027979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。